Nivolumab

Anti-PD-1 monoclonal antibody indicated for the treatment of cancer.

Nivolumab

Active Ingredient: Nivolumab

Indications for Nivolumab:

Advanced Melanoma (Non-surgical and Metastatic)
Nivolumab as monotherapy (on its own) or in combination with ipilimumab is
indicated for the treatment of advanced melanoma(a type of skin cancer)
that is unresectable (cannot be treated with surgery) or metastatic (has spread).

Specifications

Type of medication:

Biological - monoclonal antibody.

Mechanism of Action:

Anti-PD-1.

Therapeutic Area:

Oncology.

Prescription required?

Sold by prescription only.

The responsible use of medications is essential for treatment safety and efficacy. Self-medication may mask symptoms, cause adverse effects, and compromise health. Prescription medicines must be used only under the guidance of a qualified healthcare professional.